CGVYX
Price
$23.98
Change
-$0.10 (-0.42%)
Updated
Dec 17 closing price
RWIBX
Price
$64.43
Change
-$4.56 (-6.61%)
Updated
Dec 17 closing price
Ad is loading...

CGVYX vs RWIBX

Header iconCGVYX vs RWIBX Comparison
Open Charts CGVYX vs RWIBXBanner chart's image
American Funds Global Insight 529-A
Price$23.98
Change-$0.10 (-0.42%)
VolumeN/A
CapitalizationN/A
American Funds Capital World Gr&Inc R2
Price$64.43
Change-$4.56 (-6.61%)
VolumeN/A
CapitalizationN/A
CGVYX vs RWIBX Comparison Chart
Loading...
View a ticker or compare two or three
VS
CGVYX vs. RWIBX commentary
Dec 18, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CGVYX is a StrongBuy and RWIBX is a Buy.

FUNDAMENTALS
Fundamentals
RWIBX has more cash in the bank: 130B vs. CGVYX (15.2B). CGVYX pays higher dividends than RWIBX: CGVYX (1.14) vs RWIBX (1.05). CGVYX was incepted earlier than RWIBX: CGVYX (5 years) vs RWIBX (23 years). RWIBX is a more actively managed with annual turnover of: 27.00 vs. CGVYX (23.00). CGVYX (250) and RWIBX (250) have matching initial minimum investment requirements. CGVYX annual gain was more profitable for investors over the last year : 14.68 vs. RWIBX (11.34). CGVYX return over 5 years is better than : 49.36 vs. RWIBX (29.64).
CGVYXRWIBXCGVYX / RWIBX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence5 years23 years-
Gain YTD13.2869.781136%
Front LoadN/AN/A-
Min. Initial Investment250250100%
Min. Initial Investment IRAN/AN/A-
Net Assets15.2B130B12%
Annual Yield % from dividends1.141.05109%
Returns for 1 year14.6811.34129%
Returns for 3 years17.158.41204%
Returns for 5 years49.3629.64167%
Returns for 10 yearsN/A44.22-
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
LITM0.180.03
+17.46%
Snow Lake Resources Ltd
NUVB2.810.12
+4.46%
Nuvation Bio
ENTG109.362.65
+2.48%
Entegris
ARQ7.01-0.04
-0.57%
Arq
PTCT47.02-1.59
-3.27%
PTC Therapeutics